Skip to main content

Transgenomic to Buy Rights to Power3's Neurodegenerative Disease Tests

NEW YORK (GenomeWeb News) - Transgenomic said today that it has signed a letter of intent to buy the rights to Power3 Medical Products’ neurodegenerative biomarkers, including NuroPro, a blood serum-based diagnostic for Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease.
Transgenomic plans to offer NuroPro through its CLIA-certified molecular diagnostics lab.
The Power3 technology assigns a probability score that links a patient’s sample to a biostatistical model for neurodegenerative disease, and it indicates if the patient should then consult a physician.
Transgenomic’s molecular diagnostic portfolio currently includes tests for mitochondrial disorders, oncology and hematology, molecular pathology and inherited diseases.
The firm said that a final agreement is dependent on the companies negotiating a definitive exclusive license agreement, acquisition agreement, or both, and by winning approval from both companies’ boards of directors.
Transgenomic CEO Craig Tuttle said in a statement that Power3’s tests for early detection of these diseases may be particularly useful when used in combination with Transgenomics' detection and disease susceptibility tests.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.